Abstract-The renin-angiotensin-aldosterone system is involved in the arterial hypertension-associated cardiovascular remodeling. In this context, the development of cardiac fibrosis results from an imbalance between profibrotic and antifibrotic pathways, in which the role of aldosterone is yet not established. To determine the role of intracardiac aldosterone in the development of myocardial fibrosis during hypertension, we used a double transgenic model (AS-Ren) of cardiac hyperaldosteronism (AS) and systemic hypertension (Ren). The 9-month-old hypertensive mice had cardiac fibrosis, and hyperaldosteronism enhanced the fibrotic level. The mRNA levels of connective tissue growth factor and transforming growth factor-␤1 were similarly increased in Ren and AS-Ren mice compared with wild-type and AS mice, respectively. Hyperaldosteronism combined with hypertension favored the macrophage infiltration (CD68 ϩ cells) in heart, and enhanced the mRNA level of monocyte chemoattractant protein 1, osteopontin, and galectin 3. Interestingly, in AS-Ren mice the hypertension-induced increase in bone morphogenetic protein 4 mRNA and protein levels was significantly inhibited, and B-type natriuretic peptide expression was blunted. The mineralocorticoid receptor antagonist eplerenone restored B-type natriuretic peptide and bone morphogenetic protein 4 levels and decreased CD68 and galectin 3 levels in AS-Ren mice. Finally, when hypertension was induced by angiotensin II infusion in wild-type and AS mice, the mRNA profiles did not differ from those observed in Ren and AS-Ren mice, respectively. The aldosterone-induced inhibition of B-type natriuretic peptide and bone morphogenetic protein 4 expression was confirmed in vitro in neonatal mouse cardiomyocytes. Altogether, we demonstrate that, at the cardiac level, hyperaldosteronism worsens hypertension-induced fibrosis through 2 mineralocorticoid receptor-dependent mechanisms, activation of inflammation/galectin 3-induced fibrosis and inhibition of antifibrotic factors (B-type natriuretic peptide and bone morphogenetic protein 4). A rterial hypertension is known to induce cardiac remodeling, characterized by fibrosis, a risk factor for heart failure. Until now the hypertrophic, proinflammatory, and profibrotic actions of angiotensin II (Ang II) have been thought to be the major players in this cardiac remodeling. However, aldosterone concentrations have also been found to be inappropriately high in many hypertensive patients.
A rterial hypertension is known to induce cardiac remodeling, characterized by fibrosis, a risk factor for heart failure. Until now the hypertrophic, proinflammatory, and profibrotic actions of angiotensin II (Ang II) have been thought to be the major players in this cardiac remodeling. However, aldosterone concentrations have also been found to be inappropriately high in many hypertensive patients. 1 Aldosterone regulates sodium and potassium homeostasis, thereby regulating blood volume and pressure, and both clinical and experimental studies have demonstrated additional roles for aldosterone in cardiac remodeling. For example, mineralocorticoid receptor (MR) antagonists have been demonstrated to prevent cardiac fibrosis in patients with heart failure. 2 Recent studies have suggested that the profibrotic action of aldosterone involves an inflammatory step. 3 Two main pathways have been shown to be involved in the development of this cardiac fibrosis. The transforming growth factor (TGF)-␤1 pathway has a profibrotic effect via the phosphorylation and nuclear translocation of Smads proteins and perivascular inflammation, which results in an infiltration of macrophages and a secretion of proinflammatory molecules, such as osteopontin 4 and galectin 3, 5 which will induce the synthesis of collagen. In addition, arterial hypertension will also have a mechanical effect, because the increased stretching of the cardiac tissue will trigger an increased expression of natriuretic peptides, which play an antagonistic role in the induction of cardiac fibrosis. 6 In parallel, the bone morphogenetic proteins (BMPs) modulate TGF-␤1 action through the phospho-Smad pathway. 7 In view of these findings, we hypothesized that cardiac aldosterone may worsen the hypertension-induced cardiac fibrosis by unique mechanisms. The aim of the present study was to analyze the effect of inflammation in cardiac aldosterone-induced fibrosis and to assess the role of cardiac aldosterone on the balance between profibrotic and antifibrotic factors. Using a double-transgenic model of cardiac hyperaldosteronism associated with hypertension, this study provides the first evidence that cardiac aldosterone is associated with an early inhibition of hypertension-induced antifibrotic factors followed by an inflammation-induced osteopontin and galectin 3 expression leading to an aggravation of cardiac fibrosis.
Materials and Methods

Animals
Experimentations were conducted in agreement with the standards of animal care (National Institutes of Health Guide for the Care and Use of Laboratory Animals), and all of the animal work was approved by the appropriate local committee of Institut National de la Santé et de la Recherche Médicale Paris 7 University (No. 2010-12-02).
Double transgenic mice (aldosterone synthase [AS]-renin [Ren]) were created by crossing RenTgKC female mice with AS male mice. RenTgKC mice express a synthetic renin cDNA (Ren-2 and Ren-1d genes) using a liver-specific albumin promoter/enhancer. 8 This transgenic strain has elevated renin levels in the liver and increased Ang II in plasma. As described previously, 9 AS mice overexpress the AS in cardiomyocytes and have a 2-fold increased aldosterone concentration in the heart. AS-Ren male mice of the F1 generation were used in all of the experiments. All of the mice were viable and were studied at 9 months, unless otherwise specified.
Ang II Hypertension Model
After isoflurane (2%) anesthesia, 3-month old wild-type (WT) and AS mice were implanted SC with osmotic minipumps (ALZET, 2004) delivering 1 mg/kg per day of Ang II (Sigma-Aldrich, Saint Louis, MO) for 2 months.
Eplerenone
The MR antagonist eplerenone (Tocris, Bristol, United Kingdom) incorporated into the food was administered at 100 mg/kg per day to 6-and to 8-month-old mice for times indicated in Figure legends . Age-matched mice were used as controls.
Blood Pressure and Echocardiography
Systolic blood pressure was measured in nonanesthetized mice by the tail-cuff method, and echocardiography was performed on lightly sedated mice as described previously.
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In Vitro Studies
Isolation of neonatal mouse cardiomyocytes was performed as described previously. 11 After 72 hours of culture, plated cardiomyocytes were starved (0.2% serum) and pretreated with aldosterone (10 Ϫ7 M) overnight (37°C; 10% CO 2 ). Then, 10 Ϫ5 M Ang II was added, and after 24 hours of incubation, RNA was extracted from the cells.
Statistical Analysis
All of the results are expressed as meanϮSEM and represented in fold increase relative to control mice (WT) mean. After ANOVA analysis, a Student t test with Bonferroni correction was performed, except when indicated. Interaction between the 2 transgenes was performed by a 2-way ANOVA analysis. PϽ0.05 was considered statistically significant. Methods for immunohistochemistry, RNA/ protein isolation, and expression analysis are described in the expanded Methods section in the online-only Data Supplement.
Results
Physiological and Anatomic Indices
Ren and AS-Ren mice displayed similar levels of elevated systolic blood pressure (Tables 1 and 2 ). Plasmatic Ang II was already increased in Ren mice and was even higher in AS-Ren mice. The angiotensin-converting enzyme mRNA level and aldosteronemia were increased only in AS-Ren mice. As expected, cardiac hypertrophy was observed in both Ren and AS-Ren mice. The heart:body weight ratio was 19% higher in AS-Ren mice than in Ren mice, demonstrating that cardiac aldosterone aggravated the cardiac hypertrophy. Shortening fraction was unaltered in either of the hypertensive groups.
Hyperaldosteronism Enhanced Cardiac Fibrosis
As shown in Figure 1A , the hypertensive groups showed an important perivascular and interstitial fibrosis. In addition, cardiac aldosterone further enhanced the cardiac remodeling and fibrosis in the hypertensive hearts ( Figure 1B and Table  2 ). The expression of Col1a in the hearts of the 6-month-old mice was only increased in the AS-Ren group (Table 2 ). At 9 months of age, as shown in Figure 1C through 1E, in Ren mice the cardiac expression of the Col1a, Col3a, and Fn1 genes was increased (ϩ63%, ϩ160%, and ϩ55% versus WT, respectively; PϽ0.05), whereas in the AS-Ren mice Col1a and Fn1 genes were increased (ϩ69% and ϩ58% versus WT; respectively) and Col3a was decreased (Ϫ41% versus Ren mice; Figure 1D ). The expression of genes encoding the profibrotic factor TGF-␤1 and its cofactor connective tissue growth factor was higher in both Ren and AS-Ren than in WT and AS mice (approximately ϩ30%, PϽ0.01; approximately ϩ100%, PϽ0.05, respectively; Figure 1F and 1G). These results suggest that the expression of profibrotic factors is mainly triggered by Ang II/hypertension.
Hypertension Boosted the Aldosterone-Induced Inflammatory Response
Hearts of AS mice exhibited signs of inflammation as indicated by increased levels of monocyte chemoattractant protein 1 (MCP1) and CD68 mRNAs ( Figure 2A and 2B and Table 2 ). The hearts of 9-month-old AS-Ren mice had enhanced transcription of Cd68 (ϩ35%; PϽ0.05 versus Ren mice). The expression of these inflammatory mRNAs did not differ between AS and AS-Ren hearts. Very few CD68
ϩ / macrophages were observed in AS hearts, whereas they were dramatically increased in AS-Ren hearts, particularly in fibrotic areas ( Figure 2C ). In line with the macrophage infiltration in AS-Ren myocardium, the levels of osteopontin mRNA and of galectin 3 mRNA and protein were higher in AS-Ren than in Ren hearts (1.8-, 2.0-, and 2.1-fold, respectively; Figure 3A through 3C). Immunolabeling revealed a marked accumulation of galectin 3 in fibrotic areas of AS-Ren hearts ( Figure 3D ), whereas it was undetectable in other samples. The absence of elevated levels of osteopontin and galectin 3 in AS mice confirms that macrophages were not activated in these mice. 
Hyperaldosteronism Blunted the Expression of Antifibrotic Factors
Because fibrosis results from an imbalance between profibrotic and antifibrotic factors, we analyzed the expression pattern of genes encoding proteins such as B-type natriuretic peptide (BNP) and BMP4 known to antagonize the action of TGF-␤1 ( Figure 4A and 4B). At 9 months of age, both BNP and BMP4 mRNA levels were 4.8-and 1.7-fold higher in Ren mice than in WT mice, respectively. Interestingly, the induction in both BNP and BMP4 mRNAs was markedly blunted in AS-Ren mice (Ϫ45% and Ϫ25% of Ren values). The BMP4 protein level ( Figure 4C ) was elevated in all hypertensive mice (Ren and AS-Ren), but hyperaldosteronism partly limited this increase (Ϫ29% versus Ren mice; PϽ0.01). The BMP4 transducer p-Smad-1.5.8 had a cytoplasmic distribution in AS and WT hearts, whereas it was translocated into the nuclei of Ren and AS-Ren vascular cells ( Figure S1 , available in the online-only Data Supplement). As shown in Table 2 , these modifications in BNP expression seen in 9-month-old mice were already observed at 6 months of age. In contrast, the pattern of BMP4 expression exhibited minor changes according to the experimental group in youngest mice. The BNP target genes Timp-1 and Mmp-1 are involved in extracellular matrix deposition. We observed a dramatic induction of Timp-1 expression in AS-Ren mice (ϫ4 versus Ren, PϽ0.0001; Figure S2B ). This pattern reversely mirrored that of BNP ( Figure S2A ), whereas no change in Mmp-1 transcription could be demonstrated in the same animals ( Figure S2C ).
To further validate the inhibitory effect of aldosterone on the expression of antifibrotic factors, we used an acute model of Ang II-induced hypertension by administering Ang II via osmotic minipumps (Table S3 ). BNP and BMP4 mRNAs were both induced in response to Ang II, whereas they were inhibited in AS-Ang II mice (Ϫ84% and Ϫ36% versus WT-Ang II, respectively; Figure S3 ). Moreover, the pattern of connective tissue growth factor (CTGF) and TGF-␤ was similar in this acute model of hypertension to what was observed in the genetic models (Table S3) . Together, these observations demonstrate that cardiac aldosterone has a common mechanism of action, which is independent of the hypertensive model.
Effect of Aldosterone on BNP and BMP4 Expression in Isolated Cardiomyocytes
To further assess the role of aldosterone in the control of expression of BNP and BMP4 mRNAs, we used cultured neonatal mouse cardiomyocytes stimulated with Ang II for 24 hours. Aldosterone inhibited Bnp expression in neonatal mouse cardiomyocytes with or without Ang II stimulation ( Figure 5A ) and lowered BMP4 mRNA levels in Ang II-stimulated neonatal mouse cardiomyocytes ( Figure 5B ).
Effect of Eplerenone
To assess an involvement of MR in the observed phenotypes, 6-and 8-month-old mice were treated for 10 and 30 days, respectively, with eplerenone (Tables S4 and S5) . Eplerenone had no effect on blood pressure in AS and AS-Ren mice, whatever their age. Eplerenone had no effect on cardiac fibrosis or the transcription profile in WT mice. Early and sustained eplerenone treatment decreased fibrosis in AS-Ren mice (Ϫ28% versus untreated AS-Ren mice; PϽ0.05) and reversed the inhibitory effect of aldosterone on BNP, CD68, and galectin 3 mRNAs ( Figure 6A ) with no action on systolic blood pressure. The specific increase in BNP expression observed in eplerenone-treated AS-Ren mice was confirmed by a 48-hour eplerenone treatment in 9-month-old mice ( Figure S4 ). BMP4 expression did not vary in response to eplerenone in AS-Ren mice (Table S4 ), in line with the fact that BMP4 level in 6-month-old mice was very similar among the experimental groups (Table 2) . However, sustained eplerenone treatment increased BMP4 mRNA expression in AS-Ren mice ( Figure 6B ). This suggests that the aldosterone action was MR dependent.
Aldosterone Inhibited the Ang II-Dependent cAMP Response Element Binding Expression and Activation
To understand the MR-dependent inhibition of BNP expression by aldosterone, we measured cAMP response element binding (CREB) mRNA expression and phosphorylation level after Ang II stimulation. As indicated in Figure S5 , aldosterone inhibited the induction of CREB mRNA and decreased its phosphorylation by Ang II.
Discussion
The present study demonstrates that cardiac hyperaldosteronism worsens the hypertension-induced cardiac fibrosis by both the induction of an inflammatory profibrotic phenotype and the inhibition of antifibrotic factors. Ren mice develop an early and sustained hypertension 8 that induces major renal alterations, 12 but the cardiac phenotype had not been investigated. AS mice have no cardiac dysfunction despite a 2-fold higher intracardiac aldosterone concentration, 9 similar to what is observed in pathological situations, such as rat myocardial infarction (ϫ4.0) 13 or human hypertrophic cardiomyopathy (ϫ3.5). 1 The consequence of this cardiacrestricted increase in aldosterone levels is that the AS mice are normotensive. The double-transgenic AS-Ren mice are hypertensive at all ages and exhibit marked differences when compared with the single transgenic mice. Indeed, AS-Ren mice had the highest degree of cardiac hypertrophy and fibrosis and the highest levels of aldosterone and, although less dramatic, of Ang II. Interestingly, there was no variation in the plasmatic aldosterone concentration in Ren mice, in agreement with previous animal studies in Ang II-induced hypertension.
14 These previous studies had shown that Ang II is a potent trigger of aldosterone synthesis in the short term but not in chronic situations. In parallel, the increase in plasmatic Ang II level in AS-Ren relative to Ren might be secondary to the aldosterone-induced angiotensin-converting enzyme upregulation in the heart. 15 More intriguing, there is an elevated level of plasmatic aldosterone in AS-Ren mice relative to AS, which suggests a specific effect of Ang II on the cardiac synthesis of aldosterone. Therefore, by combining the long-term effects of cardiac hyperaldosteronism and Ang II-dependent hypertension, the AS-Ren model demonstrates its interest by the increased levels of cardiac hypertrophy and fibrosis that it may induce.
The profibrotic effects of high concentrations of Ang II or aldosterone have been well described in the literature. Aldosterone induces a marked cardiovascular fibrosis in experimental models but only when it is combined with a high-salt diet. 16 Accordingly, there was no fibrosis in AS mice, as already observed. 9 In both of the hypertensive groups, the progressive upregulation of Col1 and Fn genes between 6 and 9 months provided evidence for an ongoing process of ventricular fibrosis. This was confirmed by the fibrosis score and the levels of TGF-␤1 and CTGF that were only elevated in hypertensive mice. Nevertheless, the higher levels of fibrosis observed in AS-Ren mice compared with Ren, which both had similar levels of hypertension, indicate that hyperaldosteronism has a potentiating action on cardiac fibrosis through additional mechanisms.
Aldosterone has been demonstrated to trigger an inflammatory process in different pathological situations, 3, 16 thereby exacerbating the development of cardiac fibrosis. Sun et al 3 observed an induction of inflammatory markers associated with the infiltration of macrophages into the hearts of aldosterone/NaCl-treated rats. Recent insights have been brought by deletion of MR specifically in macrophages, which markedly reduced the cardiac oxidative stress, inflammation, and cardiac fibrosis induced by N G -nitro-L-arginine methyl ester/Ang II or deoxycorticosterone acetate/salt treatment. 17 In contrast, deletion of MR specifically in fibroblasts or in cardiomyocytes has no effect on the development of cardiac fibrosis. 18 The present study confirms and extends our current understanding of the inflammatory response to aldosterone in the heart. First, aldosterone is sufficient to trigger the expression of monocyte chemoattractant protein 1 and CD68 in AS-mouse hearts, whereas hypertension alone does not. Second, the hypertension-induced fibrosis is worsened by the aldosterone-induced inflammation, as demonstrated by monocyte chemoattractant protein 1 and CD68 expression and the massive infiltration of macrophages into the fibrotic areas of AS-Ren mice.
The activated macrophages secrete the profibrotic factors osteopontin and galectin 3. 4, 5 We demonstrate that the dramatic induction of these molecules results from the proinflammatory effect of aldosterone combined with hypertension. Galectin 3 expression in hearts appears to be unrelated to that of TGF-␤1, in agreement with observations made in the kidney. 19 Conversely, osteopontin might regulate the release of galectin 3 by macrophages. 20 According to Sharma et al, 5 galectin 3 leads to cardiac fibrosis by a differential increase in collagen I more than collagen III. Thus, galectin 3 is likely to be involved in the preferential stimulation of Col1a in AS-Ren. Altogether, these observations combined with the eplerenone-driven inhibition of the effects of aldosterone on CD68 and galectin 3 expression in AS-Ren mice suggest that an MR signaling in macrophages is required to elicit, through osteopontin and galectin 3 expression, the cardiac fibrosis associated with severe hemodynamic and hormonal challenges in mature mice.
Our results also show that neither TGF-␤1 nor CTGF expression is modulated by cardiac aldosterone, whereas Ang II and/or hypertension are potent inducers. These data are in total agreement with some of the previous studies 21 but in contrast with others, suggesting that aldosterone, per se, stimulates the expression of TGF-␤1 3 and of CTGF 22 in cardiac cells. It has been proposed that prorenin via the activation of extracellular-regulated kinase 1/2 mean arterial pressure-kinase upregulates TGF-␤1, collagens, and fibronectin, these effects being independent of Ang II synthesis. 23 Although Ren mice also have a high level of circulating prorenin (ϫ8), this pathway can be excluded, because a similar phenotype was observed in Ang II-infused mice (please see the online-only Data Supplement). In addition, according to Lea et al, 21 TGF-␤1 and CTGF upregulation depends mainly on hypertension and Ang II.
One major finding of this study is the fact that aldosterone inhibits the antifibrotic factors BNP and BMP4. To our knowledge, this is the first report of an aldosterone inhibitory effect on naturetic peptide expression. It is now well established that, during severe hypertension or cardiac failure, high levels of naturetic peptides are secreted by the cardiomyocytes and are released into the blood and that an improvement of the load conditions of the heart induces the decrease of plasma naturetic peptides. In relation to the present study, it should be noted that clinical trials have shown a decreased BNP expression in patients with heart failure treated with spironolactone or eplerenone. 24 However, in these studies, the decrease of BNP expression was always associated with an improvement in cardiac function. In the present study, the observation that BNP was induced in hypertensive Ren and WT mice perfused with Ang II but not in hypertensive AS mice was unexpected. Because blood pressure was identical in both AS-Ren and Ren mice and because the cardiac function of AS-Ren mice was normal, one may assume that the BNP inhibition was not related to changes in the load conditions of the heart. Moreover, the in vitro experiments validate the aldosterone inhibitory effect on BNP expression. Thus, the blockade of BNP and BMP4 expressions in AS-Ren must depend on the elevated concentration of aldosterone in heart and mediated through the MR.
The mechanisms by which aldosterone/MR inhibit the induction of NPs in the hypertensive myocardium remain unknown. This transcriptional inhibition might occur through a direct effect on the gene transcription, because there is a consensus MR and glucocorticoid receptor response element in the promoter of the Nppa gene. 25 Alternatively, it could involve the cAMP/CREB signaling pathway, which is known to regulate NP transcriptional expression 26 and which is downregulated by aldosterone. 27, 28 Moreover, the in vitro and in vivo experiments validate the aldosterone-mediated inhibition of CREB expression and activation. The cardiac NPs have beneficial effects on cardiac function through their natriuretic, aldosterone-inhibiting, and antifibrotic effects via the guanylyl cyclase-A receptor. 29 The antifibrotic effects of NPs result both from a decreased collagen synthesis and an increased matrix metalloproteinase synthesis and activity. 29, 30 In addition, NPs also decrease the expression of the tissue inhibitors of metalloproteinase (TIMP) 1 and TIMP-2, in vitro and in vivo. 31 The imbalance between the matrix metalloproteinases and the TIMPs increases the extracellular matrix protein turnover and favors tissular remodeling. The fact that, in hypertensive groups, the lowest BNP level corresponds with the highest fibrotic score could be because of the strong TIMP-1 induction in AS-Ren mice. Thus, during hypertension, aldosterone through the inhibition of NPs favors TIMP-1 expression and, in turn, fibrosis.
In addition, aldosterone inhibited the cardiac expression of BMP4 both in vivo in the 2 hypertension models and in vitro in isolated cardiomyocytes. BMP4 belongs to the TGF-␤ family.
32 BMP4 is known to favor differentiation during cardiac embryogenesis. 33 In vascular smooth muscle cells, concerted BMP4 and TGF-␤1 stimuli promote cell differentiation. 34 Downstream BMP4 signaling involves the Smad-1.5.8 phosphorylation and its nuclear translocation. 32 Interestingly, in both Ren and AS-Ren hearts, the nuclei positive for p-Smad 1.5.8 were mainly detected in the coronary smooth muscle cells, suggesting that they represent a target for BMP4. In view of these data, we may speculate that the aldosterone-induced repression of BMP4 signaling impairs the TGF-␤/BMP4 mechanistic pathway in coronary smooth muscle cells, resulting in a profibrotic phenotype. At present, very little is known about BMP4 transcriptional regulation, although several studies in embryonic models have demonstrated that GATA4 and GATA6 are major regulators of its gene expression. 35, 36 Because MR may bind to the GATA4 transcription factor, 37 a direct action of aldosterone/MR on BMP4 may be envisioned.
Perspectives
Using combined hypertension and cardiac hyperaldosteronism in both in vivo and in vitro studies, we demonstrate that the profibrotic effect of aldosterone is mainly attributed to the early and sustained inhibition of the antifibrotic factors followed by a proinflammatory activation, disturbing the balance between the profibrotic and the antifibrotic factors ( Figure 7) . These results identify new targets for aldosterone, which will help us to better understand its profibrotic effect and define new strategies to target cardiac fibrosis. In addition, the inhibition of MR can reset the TGF-␤/BMP balance and improves the action of the antifibrotic molecules, confirming the use of MR blockade as a major antifibrotic therapy. 
METHODS
Blood Pressure and hormones
Systolic blood pressure was measured in unanesthetized mice by the tail-cuff method (Kent Scientific Corporation, Torrington, USA). Animals were accustomed for several days before measurements. Aldosterone and Angiotensin II plasmatic concentrations were measured with ELISA kits: Aldosterone EIA monoclonal kit (Interchim, Montluçon, France) and EIA-AngII-1 (TebuBio, Le Perray en Yvelines, France).
Echocardiography
Echocardiographic images were acquired using a 13-MHz linear-array transducer with a digital ultrasound system (Vivid 7, GE Medical Systems, Paris, France) in lightly sedated mice (ketamine 80 mg/kg administered intraperitoneally). From a short axis view at the level of the papillary muscles, left atrial end-systole diameter, end-diastolic left ventricular (LV) septal and postero-lateral thicknesses as well as LV diameters (for computation of the shortening fraction) were measured using M-Mode 1
Cardiac fibrosis
Equatorial cryostat sections (7µm) of the ventricles were stained with the collagen specific Sirius red stain (0.5% in saturated picric acid). The ratio of interstitial collagen surface to total ventricular surface was determined with IPLab software. Quantification of fibrosis was performed in a blind fashion on at least five areas per heart. 
Immunofluorescence analysis
RNA extraction and PCR
RNA was isolated using the RNeasy Mini Kit (Qiagen, Courtaboeuf, France) according to the manufacturer's instructions. Eventual remaining DNA was digested with DNase I (Qiagen). Reverse transcription was performed with Ready-to-go You-Prime First-Strand Beads kit (GE Healthcare) with 2µg of RNA and 0.5µg of oligo dT (Invitrogen, Saint Aubin, France). Finally, real-time amplification was performed with Mastercycler Realplex2 (Eppendorf, Le Pecq, France) using the MESA BLUE qPCR MasterMix Plus for SYBR® Assay No ROX (Eurogentec, Angers, France). mRNAs data were normalized by the abundance of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA for each sample and expressed as the relative change compared with the control sample. Primers are listed in Supplemental Table 1 .
Western blot analysis
Heart tissue was lysed and homogenized in a lysis buffer (50mM Tris HCl pH7.4, 1mM EDTA, 150 mM NaCl) with 1% triton (p-Smads, Galectin3) or 1% NP40 (BMP4). Tissue sample lysate was incubated 1h on ice before clearing by centrifugation. The pellets dissolved in 1% SDS and the supernatants were quantified with Pierce BCA Protein Assay Kit (Thermo Fischer Scientific, Brebières, France). 20 µg of protein were fractionated on a 4-20% polyacrylamide gel (Invitrogen) and transferred to 0.2-µm nitrocellulose membrane. Nitrocellulose blots were blocked and incubated with mouse anti-Galectin3 (Thermo Fischer Scientific, 1/1000), mouse anti-BMP4 (Millipore, 1/1000), rabbit anti-Phospho Smad 1.5.8 (Cell Signaling, 1/1000) overnight at 4°C. Blots were incubated with goat anti-rabbit (1/5000, Sigma-Aldrich) or sheep anti-mouse horseradish Peroxidase-Linked for 1 h at room temperature before being incubated with ECL Plus (GE Healthcare). Chemiluminescence was measured using a LAS 3000 (Fuji, Courbevoie, France) and MultiGauge V2.02 software (Fuji).
SUPPLEMENTAL RESULTS
A major finding of this study is the inhibition of antifibrotic factors (BNP, BMP4) expression by aldosterone in the hypertensive heart (see the main manuscript). In order to understand the mechanistic consequences of this inhibition we looked to BNP and BMP4 downstream targets expression.
The BMP4 transducer p-Smad-1.5.8 had a cytoplasmic restricted distribution in AS and WT hearts, whereas it was also detected in nuclei of hypertensive Ren and AS-Ren cardiac vascular cells (supplemental Figure S1) . The BNP target genes Timp-1 and Mmp-1 are involved into ECM deposition. We observed a dramatic induction of Timp-1 expression in AS-Ren mice (4-fold higher than in Ren mice, p<0.0001; supplemental Figure S2B ). This pattern reversely mirrored that of BNP (supplemental Figure 2A) whereas no change in Mmp-1 transcription was noticed in the same animals (Supplemental Figure S2C) .
To further validate the inhibitory effect of aldosterone on antifibrotic factor expression, we used a more acute model of AngII-induced hypertension through osmotic minipumps (Supplemental Table S3 ). AngII infusion caused an increase of systolic blood pressure in WT and AS mice associated with cardiac hypertrophy (HW/BW) and fibrosis (LV fibrosis %) without significant differences between the two groups.
As expected BNP and BMP4 mRNAs were induced in response to AngII. Interestingly, the Bnp and Bmp4 transcription was inhibited in AS-AngII mice (-84% and -36% vs WT-AngII, respectively), demonstrating that cardiac aldosterone acts independently whatever the hypertension model (Supplemental Figure S3 ).
To assess an involvement of MR in the observed phenotypes, 6-and 8-month-old mice were treated for 10 and 30 days, respectively with eplerenone (Supplemental Tables S4-S5) . Eplerenone decreased cardiac fibrosis in AS-Ren mice (as shown in Figure 6A ) and restored BNP and BMP4 levels and decreased CD68 and galectin-3 levels in AS-Ren mice (Supplemental Tables S4-S5 ).
To further validate the MR-dependent aldosterone effect on BNP expression, we treated 9-month old AS-Ren mice with eplerenone for 48h, which was sufficient to reverse the inhibitory effect of aldosterone as indicated by the increase of BNP expression (Supplemental Figure S4 ). Supplemental Figure S5 demonstrates that aldosterone inhibited the AngII-induced CREB expression and phosphorylation, which is consistent with a CREB-dependent mechanism for the aldosterone-induced BNP inhibition observed in AS-Ren mice.
Supplemental table S1. RT-qPCR Primers list
Forward and reverse primers sequences used to quantify gene expression by RT-qPCR. 
Gene
